Skip to main content
Erschienen in: Journal of Nuclear Cardiology 3/2013

01.06.2013 | Original Article

Comparison of hemodynamic and stress testing variables in patients undergoing regadenoson stress myocardial perfusion imaging to regadenoson with adjunctive low-level exercise myocardial perfusion imaging

verfasst von: Rafael Cabrera, MD, Zehra Husain, MD, Gurunanthan Palani, MD, Aarthee S. Karthikeyan, BS, Zain Choudhry, BS, Sunita Dhanalakota, MD, Ed. Peterson, PhD, Karthik Ananthasubramaniam, MD, FACC, FASE, FASNC, FRCP (Glas)

Erschienen in: Journal of Nuclear Cardiology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Regadenoson (REG), a selective adenosine A2a receptor agonist, is becoming the preferred pharmacologic agent for stress myocardial perfusion imaging (MPI). Hemodynamic and stress variables, immediate safety and use of aminophylline when using REG combined with low-level exercise (REG WALK MPI) compared with REG MPI, have not been well studied and formed the basis of our study.

Methods

Retrospective evaluation of patients who underwent REG MPI (n = 887) was compared to patients undergoing REG WALK MPI (n = 485) from January to November 2009. Patient demographics, hemodynamic parameters, REG MPI data, side effects, immediate major clinical events, and use of aminophylline were evaluated.

Results

Patients in REG WALK MPI group tended to be younger, male and obese compared to patients in REG MPI group. REG WALK MPI patients had higher stress heart rate (103 ± 20.5 vs 84 ± 19 bpm, P = .001), higher heart rate reserve (36.3 ± 19 vs 14.7 ± 15.5 bpm, P < .001), and greater systolic blood pressure rise (4.8 ± 21.3 vs −8.9 ± 19.8 mm Hg, P < .001), compared to REG MPI patients. No major adverse events were reported immediately after REG WALK MPI. There were no differences in drug-related side effects in between the two groups; however, the use of aminophylline was lower in REG WALK MPI Group (5.6% vs 11.4%, P = .001).

Conclusion

REG WALK MPI gives more favorable hemodynamic response with lesser use of aminophylline and no increase in adverse events when compared with REG MPI.
Literatur
1.
Zurück zum Zitat Jaroudi WA, Iskandrian AE. Regadenoson: a new myocardial stress agent. J Am Coll Cardiol 2009;54:1123-30.PubMedCrossRef Jaroudi WA, Iskandrian AE. Regadenoson: a new myocardial stress agent. J Am Coll Cardiol 2009;54:1123-30.PubMedCrossRef
3.
Zurück zum Zitat Palani G, Husain Z, Cabrera R, Karthikeyan V, Karthikeyan AS, Ananthasubramaniam K. Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis. J Nucl Cardiol 2011;18:605-11.PubMedCrossRef Palani G, Husain Z, Cabrera R, Karthikeyan V, Karthikeyan AS, Ananthasubramaniam K. Safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic kidney disease patients not on hemodialysis. J Nucl Cardiol 2011;18:605-11.PubMedCrossRef
4.
Zurück zum Zitat Botvinick EH. Current methods of pharmacologic stress testing and the potential advantages of new agents. J Nucl Med Technol 2009;37:14-25.PubMedCrossRef Botvinick EH. Current methods of pharmacologic stress testing and the potential advantages of new agents. J Nucl Med Technol 2009;37:14-25.PubMedCrossRef
5.
Zurück zum Zitat Spicuzza L, Di Maria G, Polosa R. Adenosine in the airways: implications and applications. Eur J Pharmacol 2006;533:77-88.PubMedCrossRef Spicuzza L, Di Maria G, Polosa R. Adenosine in the airways: implications and applications. Eur J Pharmacol 2006;533:77-88.PubMedCrossRef
6.
Zurück zum Zitat Auchampach JA, Bolli R. Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges. Am J Physiol 1999;276:H1113-6.PubMed Auchampach JA, Bolli R. Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges. Am J Physiol 1999;276:H1113-6.PubMed
7.
Zurück zum Zitat Gemignani AS, Abbott BG. The emerging role of the selective A2A agonist in pharmacologic stress testing. J Nucl Cardiol 2010;17:494-7.PubMedCrossRef Gemignani AS, Abbott BG. The emerging role of the selective A2A agonist in pharmacologic stress testing. J Nucl Cardiol 2010;17:494-7.PubMedCrossRef
8.
Zurück zum Zitat Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther 2006;316:695-702.PubMedCrossRef Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther 2006;316:695-702.PubMedCrossRef
9.
Zurück zum Zitat Thomas GS, Thompson RC, Miyamoto MI, Ip TK, Rice DL, Milikien D, et al. The RegEx trial: a randomized, double blind, placebo and active-controlled pilot study combining regadenoson, a selective A2A adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2009;16:63-72.PubMedCrossRef Thomas GS, Thompson RC, Miyamoto MI, Ip TK, Rice DL, Milikien D, et al. The RegEx trial: a randomized, double blind, placebo and active-controlled pilot study combining regadenoson, a selective A2A adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2009;16:63-72.PubMedCrossRef
10.
Zurück zum Zitat Pennel DJ, Mavrogeni SI, Forbat SM, Karwatowski SP, Underwood SR. Adenosine combined with dynamic exercise for myocardial perfusion imaging. J Am Coll Cardiol 1995;25:1300-9.CrossRef Pennel DJ, Mavrogeni SI, Forbat SM, Karwatowski SP, Underwood SR. Adenosine combined with dynamic exercise for myocardial perfusion imaging. J Am Coll Cardiol 1995;25:1300-9.CrossRef
11.
Zurück zum Zitat Thomas GS, Miyamoto MI. Should simultaneous exercise become the standard for adenosine myocardial perfusion imaging? Am J Cardiol 2004;94:3D-10D. (discussion 10D-11D).PubMedCrossRef Thomas GS, Miyamoto MI. Should simultaneous exercise become the standard for adenosine myocardial perfusion imaging? Am J Cardiol 2004;94:3D-10D. (discussion 10D-11D).PubMedCrossRef
12.
Zurück zum Zitat Kwon DH, Cerqueira MD, Young R, Houghtalling P, Lieber E, Menon V, et al. Lessons from the regadenoson and low-level treadmill/regadenoson myocardial perfusion imaging: initial clinical experience in 1263 patients. J Nucl Cardiol 2010;17:853-7.PubMedCrossRef Kwon DH, Cerqueira MD, Young R, Houghtalling P, Lieber E, Menon V, et al. Lessons from the regadenoson and low-level treadmill/regadenoson myocardial perfusion imaging: initial clinical experience in 1263 patients. J Nucl Cardiol 2010;17:853-7.PubMedCrossRef
13.
Zurück zum Zitat Hansen CL, Goldstein RA, Akinboboye OO, Berman DS, Botvinik EH, Churchwell KB, et al. Myocardial perfusion and function: single photon emission computed tomography. J Nucl Cardiol 2007;14:e39-60.PubMedCrossRef Hansen CL, Goldstein RA, Akinboboye OO, Berman DS, Botvinik EH, Churchwell KB, et al. Myocardial perfusion and function: single photon emission computed tomography. J Nucl Cardiol 2007;14:e39-60.PubMedCrossRef
14.
Zurück zum Zitat Gauda EB, Northington FJ, Linden J, Rosin DL. Differential expression of A2A, A1-adenosine and D2-dopamine receptor genes in rat peripheral arterial chemoreceptors during postnatal development. Brain Res 2000;872:1-10.PubMedCrossRef Gauda EB, Northington FJ, Linden J, Rosin DL. Differential expression of A2A, A1-adenosine and D2-dopamine receptor genes in rat peripheral arterial chemoreceptors during postnatal development. Brain Res 2000;872:1-10.PubMedCrossRef
15.
Zurück zum Zitat Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Therapy 2006;316:695-702.CrossRef Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Therapy 2006;316:695-702.CrossRef
16.
Zurück zum Zitat Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 2008;1:307-16.PubMedCrossRef Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 2008;1:307-16.PubMedCrossRef
17.
Zurück zum Zitat Mahmarian JJ, Cerqueira MD, Iskandrian AE, Bateman TM, Thomas GS, Hendel RC, et al. Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial. JACC Cardiovasc Imaging 2009;2:959-68.PubMedCrossRef Mahmarian JJ, Cerqueira MD, Iskandrian AE, Bateman TM, Thomas GS, Hendel RC, et al. Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial. JACC Cardiovasc Imaging 2009;2:959-68.PubMedCrossRef
18.
Zurück zum Zitat Doukky R, et al. Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging: ‘the ASSUAGE trial’. J Nucl Cardiol 2012;19:448-57.PubMedCrossRef Doukky R, et al. Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging: ‘the ASSUAGE trial’. J Nucl Cardiol 2012;19:448-57.PubMedCrossRef
19.
Zurück zum Zitat Husain Z, Palani G, Cabrera R, Karthikeyan AS, et al. Hemodynamic response, arrhythmic risk, and overall safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and asthma patients. Int J Cardiovasc Imaging 2012;28:1841-9.PubMedCrossRef Husain Z, Palani G, Cabrera R, Karthikeyan AS, et al. Hemodynamic response, arrhythmic risk, and overall safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and asthma patients. Int J Cardiovasc Imaging 2012;28:1841-9.PubMedCrossRef
Metadaten
Titel
Comparison of hemodynamic and stress testing variables in patients undergoing regadenoson stress myocardial perfusion imaging to regadenoson with adjunctive low-level exercise myocardial perfusion imaging
verfasst von
Rafael Cabrera, MD
Zehra Husain, MD
Gurunanthan Palani, MD
Aarthee S. Karthikeyan, BS
Zain Choudhry, BS
Sunita Dhanalakota, MD
Ed. Peterson, PhD
Karthik Ananthasubramaniam, MD, FACC, FASE, FASNC, FRCP (Glas)
Publikationsdatum
01.06.2013
Verlag
Springer US
Erschienen in
Journal of Nuclear Cardiology / Ausgabe 3/2013
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-012-9671-1

Weitere Artikel der Ausgabe 3/2013

Journal of Nuclear Cardiology 3/2013 Zur Ausgabe

Journal of Nuclear Cardiology News Update

Advocacy: Defining quality in the field

Nuclear cardiology in the literature

A selection of recent original research papers

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.